ArticleInfluenza and other respiratory viruses2025
Respiratory Syncytial Virus Incidence in Young Children in the United States: Impact of Methodologies and Patient Characteristics.
Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- How I Treat: Immune dysregulation in Down syndrome.Journal of human immunity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesThis study aimed to estimate the incidence of respiratory syncytial virus (RSV) infections in US inpatient and outpatient settings.
methodsWe established national cohorts of privately insured children < 5 years (2011-2019) to estimate annual and seasonal incidences of lower respiratory tract infection (LRTI), RSV-LRTI, and RSV acute respiratory infection (RSV-ARI), stratified by age and high-risk conditions per American Academy of Pediatrics definitions. Sensitivity analyses varied episode definitions and assessed the impact of immunoprophylaxis and RSV under-ascertainment.
resultsAmong 6,767,107 children, annual RSV-LRTI rates dropped with increasing age in both inpatient (7.9 for age < 1 year to 0.2 for age 4 per 1000 person-years) and outpatient settings (48.3 to 1.6). Most RSV-ARI (~80%-90%) was RSV-LRTI. RSV-LRTI accounted for > half of LRTI hospitalizations among infants (7.9 RSV-LRTI versus 14.7 LRTI) and for ~20% outpatient LRTI (48.3 versus 250.3), but this contribution declined with older age. Outpatient RSV-LRTI was > 5 times inpatient rates. Inpatient RSV-LRTI rates dropped consistently with increasing gestational age (GA) (35.6 for GA < 29 weeks versus 7.6 for term infants), while outpatient rates were similar across GA groups (54.0 versus 51.6). Infants with Down syndrome had the highest RSV-LRTI rates, and any high-risk group had rates >2 times higher than healthy term infants. Across all strata, seasonal rates were > 2 annual rates. Modeling suggested that claims data captured 42% of all RSV episodes.
conclusionThis study provides national, population-based estimates of medically attended RSV infections across age groups and high-risk strata. Results allow granular assessments of disease burden to guide recommendations for new RSV prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.